Neuropathy in Uterine Cancer Treatment: Incidence and Management

Chemotherapy for uterine (endometrial) cancer especially regimens that include paclitaxel with carboplatin can commonly cause peripheral neuropathy (nerve damage), leading to numbness, tingling, pain, or weakness in hands and feet. ^[1] This side effect is well-recognized across many anti-cancer drugs, with sensory symptoms typically starting in the fingers and toes and sometimes spreading in a “glove-and-stocking” pattern as treatment continues. ^[2]

How common is neuropathy with uterine cancer treatments?

• Paclitaxel (a taxane) is a key contributor to chemotherapy-induced peripheral neuropathy and is considered dose-limiting in many patients. ^[3] In endometrial cancer regimens using carboplatin and paclitaxel, clinicians monitor neuropathy at each visit and may need to reduce, delay, or omit paclitaxel if neuropathy reaches grade 2 or higher. ^[4]
• Peripheral neuropathy from anticancer drugs most often presents as symmetrical sensory changes; severity and onset vary by drug class and cumulative dose. ^[2]
• Platinum agents (like cisplatin) can also cause neuropathy, which is often cumulative and may temporarily worsen (“coasting”) after treatment stops; symptoms may improve with dose reductions or delays. ^[5]

Bottom line: Neuropathy is a common and clinically significant side effect of standard carboplatin–paclitaxel therapy used in uterine cancer, and it frequently guides dose adjustments. ^{[4] [3]}

What does neuropathy feel like?

• Numbness, tingling, pins-and-needles, burning pain, or weakness, usually starting in the toes and fingers. ^[2]
• It is typically symmetrical and can progress to affect hands and feet in daily activities. ^[2]

Signs to report promptly: Worsening numbness, pain that interferes with sleep or daily tasks, trouble with buttons or fine motor tasks, or balance issues. ^[6]

Clinical management during chemotherapy

• For endometrial cancer regimens including paclitaxel, management is guided by toxicity grade:
  • If grade 2 neuropathy persists at the start of the next cycle, treatment is delayed until symptoms improve to grade 1 or less and paclitaxel dose is reduced by 25% in subsequent cycles. ^[7]
  • If delays exceed 3 weeks or neuropathy recurs, paclitaxel may be stopped. ^[7]
  • Grade 3–4 neuropathy typically leads to omission of paclitaxel. ^[7]
• Routine assessment for neuropathy is recommended before each cycle; dose reduction, delay, or omission may be required for grade ≥2 symptoms. ^[4]

Why dose changes matter: Reducing exposure to neurotoxic agents helps prevent progression and can improve the chance of symptom recovery over time. ^[2]

Symptom relief and evidence-based treatments

• Duloxetine (an antidepressant that also treats nerve pain) has the strongest clinical evidence and is recommended by expert groups for painful chemotherapy-induced neuropathy; it can reduce pain intensity and improve function in many people. [PM18] [PM16]
• Other medications (gabapentin, tricyclic antidepressants, topical agents) have mixed or limited evidence for CIPN; some may help select individuals but are not consistently effective across trials. [PM17]
• Non-drug strategies (see below) are often combined with medications to improve outcomes. ^[8]

Important note: Many neuropathy symptoms improve over months after finishing paclitaxel, though recovery can be incomplete and varies among individuals. ^[2]

Non-drug strategies and self-care

• Regular exercise and physical therapy can help maintain strength, balance, and function, and may reduce the impact of neuropathy on daily life. ^[6]
• Protect hands and feet: wear warm gloves/socks in cold weather, use sturdy shoes, and be careful with hot surfaces since heat sensation may be reduced. ^[6]
• Limit alcohol and avoid smoking, as these can worsen nerve health. ^[6]

Safety tips: Avoid heating pads or very hot compresses to prevent burns if sensation is reduced. ^[9]

Can neuropathy be prevented?

• Cryotherapy (cooling hands and feet during paclitaxel infusion using frozen gloves/socks) has shown potential benefits in some trials by reducing objective and subjective neuropathy measures, though findings are mixed and tolerability can be an issue. [PM29] [PM30] [PM31]
• Practical protocols for cryotherapy suggest applying frozen gloves/socks starting before infusion, replacing them every 30 minutes, and continuing briefly after the infusion ends, with close comfort monitoring. ^[10]
• Randomized pilot data with crushed ice showed variable outcomes; ongoing research continues to refine methods and confirm benefits. [PM27]

Takeaway: Cooling may help some people receiving paclitaxel, but benefits are not guaranteed and it should be done under clinical guidance to ensure safety and tolerability. [PM31] ^[10]

When to contact your care team

• New or worsening numbness, tingling, burning pain, or weakness in hands/feet.
• Trouble with fine motor tasks, balance, or walking safety.
• Symptoms interfering with sleep, work, or daily activities.

Early reporting allows timely dose adjustments and supportive care to prevent progression. ^{[4] [7]}

---

Quick Reference: Management Actions in Carboplatin–Paclitaxel Regimens

Scenario	Typical Action
Grade 2 neuropathy at start of next cycle	Delay until ≤ Grade 1; reduce paclitaxel dose by 25% thereafter. [7]
Delay >3 weeks or recurrence after reduction	Consider ceasing paclitaxel. [7]
Grade 3–4 neuropathy	Omit paclitaxel. [7]
Any cycle	Assess neuropathy prior to each treatment; dose reduce/delay/omit for grade ≥2. [4]

---

Key Points to Remember

• Neuropathy is common with paclitaxel-based chemotherapy used for uterine cancer. ^{[4] [3]}
• Duloxetine is the most supported medication for painful chemotherapy-induced neuropathy. [PM18] [PM16]
• Cooling strategies during paclitaxel may help some individuals, but evidence is mixed and comfort limits use. [PM29] [PM31] ^[10]
• Regular exercise, safety precautions, and early symptom reporting can reduce impact and improve outcomes. ^{[6] [8]}

If you’d like, I can help you prepare a personalized plan to discuss with your oncology team, including whether cryotherapy is practical in your infusion center and how to monitor symptoms at home.